Drug Trial Radar · NCT05574894
Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
692
Actual
Start
Jan 1, 2021
Primary completion
Jun 30, 2022
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 38 years, up to 46 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This retrospective cohort study aims to investigate the effects of recombinant human growth hormone (rh-GH) on the euploid status of preimplantation blastocysts in AMA patients. Infertile patients aged 38-46 years old were recruited for study if they fulfill the inclusion criteria and do not have the exclusion criteria. Treatment group: Women received growth hormone (GH) supplement during antagonist protocol for ovarian stimulation. Control group: Women received antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts per stimulation cycle and per testing cycle.
Conditions
- Growth Hormone
- Advanced Maternal Age
- PGT-A
Interventions
Growth hormoneDrug
Growth hormone is supplemented during the ovarian stimulation till the day of trigger
GnRH antagonistDrug
GnRH antagonist protocol for ovarian stimulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of cycles which obtained euploid blastocystsTime frame: 1 month after oocyte retrieval
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai JIAI Genetics and IVF Institute
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.